ライフサイエンスコーパス: Genentech

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 optosis-inducing monoclonal antibody Apomab (Genentech).

2 ower than bevacizumab acquired directly from Genentech.

3 rug supply provided by Hoffmann-La Roche and Genentech.

4 ared with bevacizumab acquired directly from Genentech (25 mg/mL; P < .05).

5 At Genentech, a method employing PNGase F digestion, fluore

6 Primary Funding Source: Genentech and Novartis Pharmaceuticals.

7 F Hoffmann-La Roche-Genentech and the Breast Cancer Research Foundation.

8 titute of Neurological Disorders and Stroke, Genentech, and Codman.

9 Abbott Laboratories, Genentech, and National Cancer Institute, National Insti

10 Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy a

11 vascular endothelial growth factor antibody [Genentech, CA]) in the treatment of colorectal and other

12 ody weight anti-CD20 (rituximab; a gift from Genentech) every 21 days, starting from day -7 postinfec

13 vailable at http://www.cgl.ucsf.edu/Research/genentech/genehub-gepis/ or http://www.gepis.org/.

14 vailable at http://www.cgl.ucsf.edu/Research/genentech/gepis/.

15 A team at Genentech has developed an elegant new technique for com

16 SCLC Working Group, under the sponsorship of Genentech Inc, Roche Pharmaceuticals, and OSI Pharmaceut

17 Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA) 5 mg/kg was admi

18 Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant,

19 terization of several CE assays developed at Genentech Inc.

20 luorescence (LIF) detection was developed at Genentech Inc. as part of the control system for the qua

21 he relative effects of bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) and ranibizumab

22 ng the effect of ranibizumab (RBZ; Lucentis; Genentech, Inc, South San Francisco, CA) in patients wit

23 Hoffmann-La Roche Ltd, Genentech, Inc.

24 an Francisco, CA) and ranibizumab (Lucentis; Genentech, Inc.), using findings from a Cochrane Eyes an

25 N-linked glycans on glycoprotein products at Genentech, Inc., is a capillary electrophoresis (CE) bas

26 r 0.5 mg intravitreal ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA) or sham inject

27 Genentech investigator-initiated trial funding, Clinical

28 Company-sponsored (Genentech or Novartis) studies in DME completed as of De

29 d of cancer cell lines from ENCODE, CCLE and Genentech projects.

30 y, available on github at https://github.com/Genentech/pviz.

31 National Institutes of Health, Genentech, Roche Laboratories, Lilly Research Laboratori

32 ed anti-HER2 monoclonal antibody (Herceptin; Genentech, San Francisco, CA), should be considered for

33 esfield, UK) or erlotinib (Tarceva, OSI-774; Genentech, South San Francisco, CA) across a variety of

34 stromal tumors or anti-HER2/neu (Herceptin; Genentech, South San Francisco, CA) for treatment of bre

35 The use of trastuzumab (Herceptin; Genentech, South San Francisco, CA) in women with UPSC s

36 Ranibizumab (rhuFab V2; Lucentis, Genentech, South San Francisco, CA) is a humanized monoc

37 Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recombinant, hu

38 e anti-HER2 monoclonal antibody trastuzumab (Genentech, South San Francisco, CA), particularly in pat

39 The anti-IgE medication omalizumab (Xolair; Genentech, South San Francisco, Calif) might allow more

40 oval of the ranibizumab injection (Lucentis; Genentech, South San Francisco, California, USA) are off

41 d to hereafter by its trade name, Herceptin, Genentech USA), we have developed a versatile approach t

42 e anti-HER2 antibody trastuzumab (Herceptin, Genentech), we synthesized a trastuzumab-SPP-Rhodamine r

43 monoclonal antibody, Trastuzumab (Herceptin; Genentech), with chemotherapy is the current standard of

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。